Recombinant Human Podoplanin Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human Podoplanin Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human Podoplanin Fc Chimera (Catalog # 3670-PL) can bind Recombinant Human CLEC‑2 (Catalog # 1718-CL) with an estimated K_d <4 nM.
• Source: Mouse myeloma cell line, NS0-derived human Podoplanin protein
  

  Human Podoplanin (Glu97–Lys199) & (Ala99–Lys199) Accession # NP_006465.3	IEGRMD	Human IgG1 (Pro100–Lys330)
  N-terminus		C-terminus

• Accession #: NP_006465.3
• N-terminal Sequence: Glu97 & Ala99
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: PDPN
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 37.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-65 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Podoplanin Fc Chimera Protein, CF

• 36-KD
• Aggrus
• Gp36
• Gp38
• GP40
• HT1A-1
• hT1alpha-1
• hT1alpha-2
• lung type I cell membrane associated glycoprotein
• lung type-I cell membrane-associated glycoprotein (T1A-2)
• OTS 8
• OTS8
• PA2.26 antigen
• PDPN
• Podoplanin
• RANDAM-2
• T1A
• T1A-2
• T1-alpha

Background

Podoplanin, also known as glycoprotein 36 (gp36), PA2.26 antigen, T1-alpha (T1A), and aggrus, is a 36 kDa type I transmembrane sialoglycoprotein and member of the Podoplanin family (1-2). Podoplanin has three potential splice variants, the longest of which is represented by a 238 amino acid (aa) precursor (NP_006465). It contains an undefined signal sequence, a 22 aa transmembrane segment (aa 207-228) and a short cytoplasmic tail (aa 229-238). The ECD contains abundant Ser/Thr residues that could serve as potential O-linked glycosolation sites. The cytoplasmic tail contains putative sites for protein kinase C phosphorylation (2-3). There are two potential alternate start sites at Met 77 (Swiss Prot #: Q86YL7) and Met 119 (EAW51692) that generate short forms. The 162 aa short form Podoplanin precursor shares 47% aa identity with mouse Podoplanin. Podoplanin is expressed on glomerular epithelial cells (podocytes), type I lung alveolar cells, lymphatic endothelial cells (4-5), and numerous tumors, including colorectal tumors (3), squamous cell carcinomas (4, 6), testicular seminoma (7), and brain tumors (8-10). One study shows high expression of Podoplanin mRNA in placenta, lung, skeletal muscle, and heart, and weaker levels in brain, kidney, and liver (1). Podoplanin is the ligand for C-type lectin-like receptor 2 (CLEC-2) (2). Their association is dependent on sialic acid on O-glycans of Podoplanin (2). Through its association with CLEC-2, Podoplanin induces platelet aggregation and tumor metastasis (2). Podoplanin is also necessary for lymphatic vessel formation, normal lung cell proliferation and alveolus formation at birth (2).

1. Zimmer, G. et al. (1999) Biochem. J. 341:277.
2. Katsue-Inoue, K. et al. (2007) J. Biol. Chem. 282:25993.
3. Kato, Y. et al. (2003) J. Biol. Chem. 278:51599.
4. Schacht, V. et al. (2005) Am. J. Pathol. 166:913.
5. Breiteneder-Geleff, S. et al. (1997) Am. J. Pathol. 151:1141.
6. Kato, Y. et al. (2005) Tumour Biol. 26:195.
7. Kato, Y. et al. (2004) Oncogene 23:8552.
8. Mishima, K. et al. (2006) Acta Neuropathol. 111:563.
9. Mishima, K. et al. (2006) Acta Neuropathol. 111:483.
10. Kato, Y. et al. (2006) Biochem. Biophys. Res. Commun. 349:1301.

Publications for Podoplanin (3670-PL)(4)

Publications using 3670-PL

• CP Tseng, YL Huang, YW Chang, HR Liao, YL Chen, PW Hsieh Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2 J Food Drug Anal, 2019-09-26;28(1):115-123. 2019-09-26 [PMID: 31883599] (Bioassay, Human)
• T Muraguchi, D Nanba, EK Nishimura, T Tashiro IGF-1R deficiency in human keratinocytes disrupts epidermal homeostasis and stem cell maintenance J. Dermatol. Sci., 2019-05-11;0(0):. 2019-05-11 [PMID: 31122679] (Bioassay, Human)
• Chang C, Chung C, Hsu C, Peng H, Huang T Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation. J Thromb Haemost, 2014-04-01;12(4):540-9. 2014-04-01 [PMID: 24479713] (Bioassay)
• Bertozzi CC, Schmaier AA, Mericko P Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood, 2010-04-02;116(4):661-70. 2010-04-02 [PMID: 20363774] (Flow Cytometry, Mouse)

Bioinformatics

• Gene Symbol: PDPN
• Uniprot:
  • NP_006465.3(Human)